SKIN BARRIER RECOVERY WITH FLORAESTERS® 60

CS 11-034

2% Floraesters 60 Promotes Skin Barrier Recovery As Effectively As 5% Petrolatum



2% Floraesters 60 performed statistically significantly ($p<0.05$) better than the vehicle when compared to the baseline values and demonstrated no statistical significant difference from petrolatum three hours after application.

TEWL (transepidermal water loss) was determined using a Tewameter TM300 on normal, untreated forearm skin (baseline), followed by exposure to a 0.3% solution (w/w) of SLS (sodium lauryl sulfate) for approximately 18 hours under occlusion using 19mm Hill Top Chambers® (to break down the barrier of the skin). TEWL measurements were again taken 30 minutes following chamber removal and percent increase from baseline was determined. The forearms were then treated with the above mentioned test articles hourly for three hours followed by additional TEWL measurements an hour after each application. Percent of barrier recovery was then determined relative to the baseline values. The three hour data points from the study are illustrated in the graph on the right.

Vehicle: Water (*q.s.*), Glyceryl Stearate (and) PEG-100 Stearate (4.00%), Cetyl Alcohol (3.00%) Phenoxyethanol (and) Methylparaben (and) Ethylparaben (and) Butylparaben (and) Propylparaben (0.80%), Xanthan Gum (0.20%), and Disodium EDTA (0.03%)

Floratech Ingredient: Floraesters 60

The clinical study of Floratech® test formulation (CTL_10-033) was conducted *in vivo* on a panel of 12 healthy men and women ranging from 26 to 55 years of age with normal volar forearms. The duration of the study was 2 days with 3 applications of the test article and TEWL measurements taken under controlled temperature and humidity conditions. This study was double-blind and randomized. Hill Top Chamber is a registered trademark of Hill Top Research, Inc. (Cincinnati, OH). Tewameter is a product of Courage+Khazaka. The reference image seen above is for illustration only and was not taken during the actual study. (Clinical Study 10-033 Phase 2 report available upon request.)

REV 15DEC14

Contact: sales@floratech.com